Lv31
380 积分 2021-09-23 加入
Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial
55分钟前
待确认
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects
3小时前
已完结
Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12
3小时前
已完结
MB09, a denosumab biosimilar candidate: Biosimilarity demonstration in a phase I study in healthy subjects
3小时前
已完结
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
3小时前
已完结
Randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of the denosumab biosimilar MW031 in Chinese postmenopausal women with osteoporosis
4小时前
已完结
Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study of GB223, a Fully-Humanized Monoclonal Antibody to RANKL, in Healthy Chinese Adults
4小时前
已完结
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects
6小时前
已完结
Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study
8小时前
已完结
Long-term and sequential treatment for osteoporosis
2个月前
已完结
皖公网安备34019202002308
